A Revolutionary Radiotherapeutic Mission

RadAlliance Therapeutics, a clinical stage targeted radionuclide therapy biotech company, was founded in late 2024. The company is dedicated to the discovery and development of best-in-class diagnostic and therapeutic nuclear medicines, with a particular focus on precision oncology.